Last Updated:
First Published:
The Trump administration’s new tariffs on Canada and Mexico, and higher levies on China, don’t seem likely to have a major impact on health stocks, but investors in the sector shouldn’t be breathing easy.
While drugmakers, medical-device manufacturers, and companies that make scientific tools have far-flung manufacturing networks, those networks for the most part don’t rely heavily on either Canada or Mexico.
Read the full article here
